Anew Labs, ByteDance’s biotech spinout, raises $290M to build a China AI bio rival
read at Endpoints ↗DealPositive
Anew Labs, a biotech spinout from ByteDance, announced it has secured $290 million in funding.
The capital came from a mix of Chinese investors such as HSG, IDG Capital and Hillhouse Investment, as well as global AI players including Google and Anthropic.
The company aims to develop a China-based platform that combines artificial intelligence with biology, positioning itself as a domestic alternative to Western AI labs.
Headquarters are in Shanghai and the leadership team is headed by CEO Kai Liu.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Endpoints 11 2026 winner Anew Labs offers a China-based rival to AI labs”
read at Endpoints ↗88 words · retrieved 2h ago
comments(0)
5-min edit window · permanent after that